April 10, 2023
Eisai and Merck said on April 7 that they will call off a PIII study testing their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) for the frontline treatment of adults with unresectable or metastatic melanoma. The termination came after...read more